Improvement in baseline TSQM scores in patients that switched to avatrombopag from eltrombopag or romiplostim. Mean percent improvement from BL in TSQM domain scores on days 30 and 90/EOS in the total population (A), eltrombopag-switched subpopulation (B), and romiplostim-switched subpopulation (C).